According to AOL
New data from the U.S. Centers for Disease Control and Prevention (CDC) indicate that Candida auris (C. auris) infections continue to increase across the United States, highlighting ongoing challenges for healthcare systems. According to the latest federal surveillance data, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), the total number of reported Candida auris cases reached 6,197 in 2024, compared with 2,882 cases in 2022. Clinical infections increased by 3,315 cases during this period, while the number of colonized individuals identified through screening also nearly doubled. Although health officials note that improved surveillance and expanded screening programs may have contributed to the increase in reported cases, the continued spread of this multidrug-resistant yeast remains a significant public health concern.
Candida auris is an emerging fungal pathogen first identified in the United States in 2016. Unlike many other fungal species, it has demonstrated a remarkable ability to persist on hospital surfaces and medical equipment for extended periods, sometimes surviving for weeks despite routine cleaning procedures. The yeast primarily affects individuals with serious underlying medical conditions, including patients receiving intensive care, those requiring invasive medical devices such as central venous catheters or ventilators, organ transplant recipients, and individuals with weakened immune systems. Once the organism enters the bloodstream or other sterile body sites, it can cause severe invasive infections that may progress to sepsis, organ failure, or septic shock. Symptoms are often nonspecific and may resemble bacterial infections, making laboratory diagnosis essential for appropriate treatment.
One of the greatest challenges associated with Candida auris is its increasing resistance to antifungal medications. While echinocandins remain the recommended first-line treatment for most infections, health authorities report that resistance to available antifungal drugs continues to emerge in some strains, reducing therapeutic options. A 2022–2023 CDC laboratory analysis of more than 8,000 clinical isolates found that over 95 percent were resistant to fluconazole, 15 percent were resistant to amphotericin B, and about 1 percent were resistant to echinocandins — a small but growing proportion that has raised concern because echinocandins are the preferred first-line therapy. Another important characteristic of the pathogen is colonization, in which individuals carry the yeast on their skin or other body sites without showing symptoms. Colonized patients may continue carrying Candida auris for two years or longer and can unknowingly transmit the organism to healthcare environments and other patients. Because colonization cannot currently be eliminated with available treatments, infection prevention measures remain critical for limiting transmission within healthcare facilities.
The CDC recommends a comprehensive infection prevention strategy that includes early screening of high-risk patients, rapid laboratory identification, strict isolation precautions, routine use of gloves and gowns by healthcare workers, enhanced environmental cleaning using disinfectants effective against Candida auris, and careful hand hygiene for healthcare personnel and visitors. Screening programs play an important role because they help identify colonized individuals before widespread transmission occurs.
Researchers emphasize that Candida auris poses little risk to healthy members of the general public and primarily threatens individuals with significant medical vulnerabilities. Although the reasons behind the recent increase remain uncertain, experts suggest that expanded surveillance, improved diagnostic testing, increased patient movement between healthcare facilities, and healthcare disruptions during the COVID-19 pandemic may all have contributed to the growing number of reported cases. Continued surveillance and infection control remain essential to limiting the spread of this emerging multidrug-resistant fungal pathogen.
References
CDC, MMWR (2026). Surveillance for Candida auris — United States, 2022–2024.
According to AOL
Key Takeaways
- Centers for Disease Control and Prevention (CDC) indicate that Candida auris (C.
- Clinical infections increased by 3,315 cases during this period, while the number of colonized individuals identified through screening also nearly doubled.
- Unlike many other fungal species, it has demonstrated a remarkable ability to persist on hospital surfaces and medical equipment for extended periods, sometimes surviving for weeks despite routine cleaning procedures.
- One of the greatest challenges associated with Candida auris is its increasing resistance to antifungal medications.
- Colonized patients may continue carrying Candida auris for two years or longer and can unknowingly transmit the organism to healthcare environments and other patients.
Frequently Asked Questions
New data from the U.S. Centers for Disease Control and Prevention (CDC) indicate that Candida auris (C. auris) infections continue to increase across the United States, highlighting ongoing challenges for healthcare systems. According to the latest federal surveillance data, published in the CDCR
How does Candida auris Cases affect human health and safety?
Candida auris is an emerging fungal pathogen first identified in the United States in 2016. Unlike many other fungal species, it has demonstrated a remarkable ability to persist on hospital surfaces and medical equipment for extended periods, sometimes surviving for weeks despite routine cleaning pr
What treatment options are available for Candida auris Cases?
One of the greatest challenges associated with Candida auris is its increasing resistance to antifungal medications. While echinocandins remain the recommended first-line treatment for most infections, health authorities report that resistance to available antifungal drugs continues to emerge in som
What are the main risks associated with Candida auris Cases?
The CDC recommends a comprehensive infection prevention strategy that includes early screening of high-risk patients, rapid laboratory identification, strict isolation precautions, routine use of gloves and gowns by healthcare workers, enhanced environmental cleaning using disinfectants effective ag
What actions are recommended regarding Candida auris Cases?
Researchers emphasize that Candida auris poses little risk to healthy members of the general public and primarily threatens individuals with significant medical vulnerabilities. Although the reasons behind the recent increase remain uncertain, experts suggest that expanded surveillance, improved dia
